vialroom

#tirzepatide 2024-10-22

Tuesday35 messages7 participantstimes are UTC
Highlights from this day
  • two_four_ceiling — my VendorInvestigate result on a MKM vial came in at 99 which is why i keep buying from them 14:56
  • VialBot — Reminder set. I will post here in 8 days. 16:11
  • coelution_cai — sorry to jump in does switching from semaglutide need a gap or do you just start 19:52
AN

40 units of a 5 solution is a lot of volume and i check that one twice every single time

TO

went back to semaglutide after 6 months because the cost difference mattered more than the GI

i sat at 7.5 for 16 months and never needed more, which is where the folklore comes from

update on the earlier thing changed my mind about needing 15, i was chasing a number rather than an outcome

the GIP explanation for easier nausea is plausible and i still treat it as a story not a fact

*PeptideMeter not the other one

while im here if youre coming off semaglutide the honest answer is start low and find out, theres no table

TO

plateaued at 5 weeks the same way i did on semaglutide, so i doubt its compound specific

held 10 for 12 months and lost 11kg over that stretch, slow and boring and fine, for what its worth

TF

there is no clean conversion between the two, anyone giving you a ratio is guessing

my VendorInvestigate result on a MKM vial came in at 99 which is why i keep buying from them

MO

restarted at 2.5 after 10 months off and the first two doses reminded me why titration exists, still working it out

ok so whats the top licensed dose, 15 or does it go higher

[edited]
LN

no gap when i switched, took the last semaglutide dose and started this a week later

how long before the dual thing was noticeable to you

[edited]
LN

the two compounds arent interchangeable week for week even if the effect ends up similar, ask me again in a month

*Medutest not the other one

sorry to jump in does switching from semaglutide need a gap or do you just start

Cited study
Tirzepatide for Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA)
New England Journal of Medicine · 2024
AHI as the primary endpoint, with and without PAP therapy.